Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

Amondys 45 Gets DMD Nod From FDA

Executive Summary

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

You may also be interested in...



Sarepta’s Exondys 51 Successor On Clinical Hold, But Quick Resolution Expected

The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.

Can Sarepta Beat Pfizer To A Duchenne Gene Therapy Breakthrough?

As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.

Sarepta Charges Ahead With DMD Gene Therapy Despite Setback

The company plans to start its Phase III trial of SRP-9001 in the middle of this year, with a potential readout by the end of 2022.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel